Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
  • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q7/00—Preparations for affecting hair growth
  • A61Q7/02—Preparations for inhibiting or slowing hair growth
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
  • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
  • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
  • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/60—Salicylic acid; Derivatives thereof
  • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
  • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Definitions

• the present invention relates, in its most general aspect, to the use in a cosmetic composition or for the preparation of a pharmaceutical composition for slowing down or preventing the growth of hair and / or hair, of at least one inhibitor of l activity of retinoic acid.
• the compositions according to the present invention are also intended to delay hair loss and / or hair loss. It also relates to a non-therapeutic treatment method for modifying hair growth.
• hair growth and hair renewal are mainly determined by the activity of the hair follicles. Their activity is cyclical and essentially comprises three phases, namely the anagen phase, the catagen phase and the telogen phase.
• the active anagen phase or growth phase which lasts several years and during which the hair lengthens, is followed by a very short and transient catagen phase which lasts a few weeks, then a rest phase, called the telogen phase, which lasts some months.
• the hair falls out and another cycle begins again.
• the hair is therefore constantly renewed, and of the approximately 150,000 hairs in hair, at each instant, around 10% of them are at rest and will therefore be replaced in a few months.
• early hair loss occurs in genetically predisposed subjects and it affects men in particular. More specifically, it is androgenetic or androgenic or androgenogenetic alopecia.
• This alopecia is mainly due to a disruption of the renewal 2 capillaries which initially leads to the acceleration of the frequency of cycles at the expense of the quality of the hair and then its quantity. There is a gradual depletion of the hair by regression of the so-called "terminal" hair at the down stage. Areas are preferentially affected, in particular the temporal or frontal gulfs in men, and in women, there is a diffuse alopecia of the vertex.
• vitamins such as vitamin E, amino acids such as serine or methionine, vasodilators such as acetylcholine and its derivatives, female hormones such as estradiol, keratolytic agents such as l salicylic acid or chemical compounds such as, for example, 2,4-diamino 6-piperidinopyrimidine 3-oxide or "Minoxidil” described in US 4,596,812 or its numerous derivatives such as those described for example in patent applications EP 353123, EP 356271, EP 408442, EP 522964, EP 420707, EP 459890, EP 519819.
• Minoxidil if it remains the reference compound in the field, has significant side effects which make its use difficult.
• the discovery of substances having an effect on hair growth and / or fall without presenting annoying side effects remains a major objective of research. Furthermore, it is advantageous to find compounds capable of slowing down the growth of body hair and / or hair.
• all-trans retinoic acid acts on the differentiation and / or proliferation of cells by interacting with nuclear receptors or RARs (Retinoic Acid Receptors) contained in the cell nucleus.
• RARs Retinoic Acid Receptors
• RAR- ⁇ , RAR- ⁇ and RAR- ⁇ are three identified subtypes of RAR receptors. These receptors, after binding of the ligand (i.e. all-trans retinoic acid), interact with the promoter region of genes regulated by retinoic acid at the level of specific response elements (RARE).
• RARE specific response elements
• RAR receptor subtype ⁇ , ⁇ or ⁇
• RARs specific agonist ligand RARs
• Antagonists of retinoic acid will on the contrary inhibit the activity of retinoic acid or its metabolites at the cellular level.
• RARs antagonists which bind to the RARs receptors but do not induce the activity observed for retinoic acid or retinoids.
• RAR ⁇ receptor antagonists inhibit retinoid-induced cell differentiation on cells of the HL60 cell line or, conversely, reverse the inhibition of mouse B-cell proliferation induced by retinoids ( C. APFEL & al., Proc Natl. 4
• retinoic acid Different antagonists of retinoic acid are described in patent application EP 0 740 937. They are recommended for treating disorders and / or conditions linked to overregulation of the RAR receptors and / or to hypervitaminosis A, most often resulting in an inflammatory, allergic and / or immunological component, such as psoriasis. They are also described as treating alopecia.
• a cosmetic or pharmaceutical composition preferably dermatological, intended to slow down and / or prevent the growth of hairs and / or hair, at least one inhibitor of the activity of retinoic acid.
• a cosmetic or pharmaceutical composition preferably dermatological, intended to delay the loss of body hair and / or hair, by at least an inhibitor of retinoic acid activity.
• Inhibitors of retinoic acid activity can act in two ways, 5 first by accelerating the cellular metabolism of retinoic acid so as to decrease the cellular concentration of the latter, the second by antagonizing its action at the cellular level.
• Inhibitors of the activity of retinoic acid can therefore be, according to the invention, accelerators of the metabolism of retinoic acid or antagonists, inverse agonists or partial agonists of retinoic acid.
• retinoic acid antagonists is preferably meant according to the invention the compounds which inhibit the action of retinoic acid and / or its metabolites and / or retinoids. These are more particularly the RARs antagonists, which bind to the RARs receptors without, however, activating them.
• a process for identifying antagonistic molecules of RARs characterized in that it comprises the following steps: (i) a sufficient quantity of a molecule is applied topically to part of the skin of a mammal RAR agonist, (ii) a systemic or topical administration is administered to this same mammal or to this same part of the mammalian skin, before, during or after step (i), a molecule capable of exhibiting antagonistic activity of RARs and (iii) the response is evaluated on the part of the skin thus treated of the mammal.
• the mammal is a rodent such as a mouse, rat, guinea pig, hamster or rabbit.
• the part of the mammalian skin used can be any part of the mammalian body.
• the response on the part of the skin thus treated of the mammal to be evaluated corresponds to a clinical modification thereof. In general, this response to be evaluated corresponds to a change in the thickness of the part of the skin thus treated.
• the thickness of the part of the skin thus treated can be measured by any method known per se.
• step (iii) corresponds to a measurement of the response of the part of the skin thus treated and to a comparison of this measurement with that of the response of this same part of the treated skin, in the same conditions, with the RAR agonist molecule alone.
• the RAR agonist molecules are chosen from compounds capable of inducing the differentiation of cells (F9) from mouse embryonic teratocarcinoma.
• the secretion of the plasminogen activator which accompanies this differentiation is an index of the biological response of F9 cells to these compounds. It is also known that the capacity of these compounds to induce the plasminogen activator is directly correlated with the affinity and the activity which they have on the RAR receptors endogenous to F9 cells (Skin Pharmacol., 1990, 3, pp. 256 -267).
• RAR agonist molecules inducing the differentiation of F9 cells there may be mentioned more particularly:
• the sufficient quantity of a RAR agonist molecule to be applied corresponds to that to which a response of the treated part of the mammalian skin is observed after step (i).
• this amount varies between 0.0001% and 2% by weight per volume of solution applied.
• any technique of administration of a product by direct application of this last on a surface (or external) part of the body and by systemic way, any technique 7 administration of a product by a route other than topical, for example enteral and / or parenteral.
• a route other than topical for example enteral and / or parenteral.
• enteral and / or parenteral In the case of the systemic route, it is preferred to use the oral route.
• the antagonists of retinoic acid are in particular compounds described in patent applications EP 661 259, EP 740 937, EP 658 553, EP 568 898, WO 95/33745, WO 97/09297 and WO 94/14777, and in several scientific publications, in particular EYROLLES & al (J. Med. Chem., 37, 1994, 1508-1517; Med. Chem. Res., 2, 1992, 361-367) and KANEKO & al (Med. Chem. Res. , 1, 1991, 220-225) incorporated herein by reference and which inhibit the action of retinoic acid and / or retinoids.
• RAR antagonists useful according to the invention are in particular selected from the following compounds: 4- [7- (1-adamantyl) -6-methoxyethoxymethoxy -2-naphthyl] benzoic acid,
• RAR antagonists useful according to the invention are preferably selected from the following compounds: 4- (5,5-dimethyl-8-p-tolyl-5,6-dihydro-naphthalen-2-ylethynyl) benzoic acid,
• RAR antagonists useful according to the invention are selected from the following compounds:
• the amount of inhibitor which can be used according to the invention is of course a function of the desired effect. It also depends on the inhibitor. It can therefore vary to a large extent.
• an inhibitor of the activity of retinoic acid may contain the inhibitor in an amount representing from 0.0001% to 5% by weight total of the composition and preferably in an amount representing from 0.01% to 2% of the total weight of the composition.
• an inhibitor of the activity of retinoic acid may contain the inhibitor in an amount representing 0.001% to 15% of the total weight of the composition and preferably in an amount representing from 0.1% to 10% of the total weight of the composition.
• compositions can be conventionally packaged in a form suitable for the various modes of administration or application envisaged.
• compositions are preferably packaged in a form suitable for topical application.
• compositions according to the invention can also use various conventional and usual additives, in particular cosmetic in the case of topical applications (hair products in particular), chosen for example from UV filters, thickening agents, penetration agents such as as urea, organic solvents such as ethanol, isopropanol, alkylene glycols, surfactants chosen from nonionic surfactants such as 10 alkylpolyglycosides, cationic surfactants, anionic surfactants and amphoteric surfactants, colorants, dandruff agents, perfumes and preservatives.
• additives in particular cosmetic in the case of topical applications (hair products in particular)
• additives chosen for example from UV filters, thickening agents, penetration agents such as as urea, organic solvents such as ethanol, isopropanol, alkylene glycols, surfactants chosen from nonionic surfactants such as 10 alkylpolyglycosides, cationic surfactants, anionic surfactants and amphoteric surfactants, colorants
• compositions are chosen in such a way by those skilled in the art that they do not contravene the desired effect of the present invention.
• compositions already known as having activity in the field of slowing down and / or inhibiting the growth of hair and / or hair.
• inhibitors of cyclooxygenases and / or activators of lipoxygenases such as those cited in patent applications EP-A-94/402055, WO-A-94/27586 or WO-A- 94/27563.
• compositions already known as having activity in the field of hair loss and / or hair and / or products having activity in the treatment of alopecia. .
• the inhibitor of the activity of retinoic acid and the other active component (s) on the growth of hair and / or hair.
• the inhibitor of the activity of retinoic acid and the other active component (s) can be administered simultaneously, separately or spread over time.
• the subject of the invention is a product comprising at least one inhibitor of the activity of retinoic acid and at least one other active component as a combination product for simultaneous, separate or spread over time use to slow down and / or inhibit the growth of body hair and / or hair.
• the invention also relates to a product comprising at least one inhibitor of the activity of retinoic acid and at least one other active component as a combination product for simultaneous, separate or spread over time to delay the fall of the hairs and / or hair.
• the inhibitor of the activity of retinoic acid and the other active component (s) can be packaged separately in the form of a kit, the components of which will be mixed immediately.
• the subject of the invention is therefore a kit comprising at least one inhibitor of the activity of retinoic acid and at least one other active component for simultaneous, separate or spread over time use to slow down and / or inhibit the growth of hairs and / or hair.
• the invention also relates to a kit comprising at least one inhibitor of the activity of retinoic acid and at least one other active component for simultaneous, separate or spread over time use to delay hair loss and / or hair.
• the inhibitor of the activity of retinoic acid can be used in an amount ranging from 0.0001% to 15% by weight, preferably ranging from 0.01% to 10%.
• the cyclooxygenase inhibitor or the lipoxygenase activator can be used in an amount ranging from 0.001% to 5% by weight and preferably ranging from 0.01% to 0.1%.
• a non-therapeutic treatment method for slowing down or preventing hair growth and / or hair growth which comprises administration to the body, topically and / or systemically.
• at least one inhibitor of acid activity 12 retinoic in doses as defined above, the organism preferably being a human being.
• a non-therapeutic treatment method for delaying the loss of hair and / or hair which comprises administration to the organism, topically and / or systemically, of at least one inhibitor of the activity of retinoic acid, in doses as defined above, the organism preferably being a human being.
• the inhibitor of the activity of retinoic acid is administered topically.
• compositions as defined above are applied to the skin and / or the scalp.
• the frequency of administration or application of the compositions according to the invention is of the order of once or twice a day.
• the sufficient quantities of inhibiting agents to be used in the context of the invention can, generally, remain very low.
• the present invention finds particularly useful applications in the field of treatment of various pathologies affecting the pilosebaceous units of the skin and / or of the scalp, in particular hirsutism.
• mice Male, 42 days old are selected for their hair cycle in the resting phase (telogen phase). They are then shaved (OJ). Since melanin synthesis occurs only on hairs in the active phase, the skin of shaved mice is pink.
• the animals are divided into two groups, one receiving a composition comprising an inhibitor of the activity of retinoic acid and the other being treated with the vehicle for this composition. 50 ⁇ l of these compositions are applied daily from D1 to a shaved surface (3 cm 2 ) of the skin at concentrations varying from 0.1 to 0.3% of the inhibitor of the activity of retinoic acid.
• the animals are observed daily and the criteria corresponding to the surface thus treated are noted daily.
• the criteria are as follows:
• Criterion 0 uniformly pink skin
• Criterion 1 appearance of a gray stain color on the shaved surface
• Criterion 2 appearance of the first hair stems on the shaved surface
• Criterion 3 gray color over the entire shaved area
• Criterion 4 presence of hair over the entire shaved area
• Criterion 5 regrown hair not distinct from the hair remaining in place
• CD2665 represents 4- [7- (1-adamantyl) -6-methoxyethoxymethoxy -2-naphthyl] benzoic acid
• CD2822 represents 6- [7- (1-adamantyl) -6-methoxyethoxymethoxy-2-naphthyl] nicotinic acid
• CD3106 represents 4- (5,5-dimethyl-8-p-tolyl-5,6- acid) dihydro-naphthalen-2-ylethynyl) benzoic
• CD2848 represents 4- [7- (1-adamantyl) -6-methoxyethoxymethoxy -2-naphthyl] saiicylic acid.
• Restarting of growth and lengthening of the hair are significantly delayed in animals treated with an inhibitor of retinoic acid activity compared to animals treated with the vehicle.
• Example 2 Examples of formulations illustrating the invention. These compositions are obtained by simple mixing of the various components.
• Composition 1 Leave-in lotion
• Composition 2 Rinsed lotion

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Birds (AREA)
• Dermatology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Emergency Medicine (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cosmetics (AREA)
• Heterocyclic Compounds Containing Sulfur Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9524693

Family Applications (1)

Country Status (16)

Citations (4)

• 1998
  • 1998-03-31 FR FR9803978A patent/FR2776511B1/fr not_active Expired - Fee Related
• 1999
  • 1999-03-24 AU AU29388/99A patent/AU2938899A/en not_active Abandoned
  • 1999-03-24 KR KR1020007010470A patent/KR20010042104A/ko not_active Application Discontinuation
  • 1999-03-24 IL IL13785999A patent/IL137859A0/xx unknown
  • 1999-03-24 BR BR9908411-2A patent/BR9908411A/pt not_active IP Right Cessation
  • 1999-03-24 RU RU2000127111/14A patent/RU2193877C2/ru active
  • 1999-03-24 PL PL99343004A patent/PL343004A1/xx not_active Application Discontinuation
  • 1999-03-24 CA CA002324899A patent/CA2324899A1/fr not_active Abandoned
  • 1999-03-24 EP EP99910423A patent/EP1066017A1/fr not_active Withdrawn
  • 1999-03-24 HU HU0102411A patent/HUP0102411A3/hu unknown
  • 1999-03-24 CN CN99804411A patent/CN1298290A/zh active Pending
  • 1999-03-24 WO PCT/FR1999/000687 patent/WO1999049838A1/fr not_active Application Discontinuation
  • 1999-03-24 JP JP2000540805A patent/JP2002509870A/ja active Pending
  • 1999-03-30 AR ARP990101412A patent/AR015551A1/es unknown
• 2000
  • 2000-08-29 ZA ZA200004483A patent/ZA200004483B/en unknown
  • 2000-09-28 NO NO20004880A patent/NO20004880L/no unknown

Patent Citations (5)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events